Citigroup Inc Next Cure, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$2.72 - $5.19 $255 - $487	-94 Reduced 22.33%	327 $1,000
Q2 2022 Aug 10, 2022	SELL	$3.38 - $5.27 $584 - $911	-173 Reduced 29.12%	421 $2,000
Q1 2022 May 12, 2022	SELL	$4.76 - $6.24 $1,142 - $1,497	-240 Reduced 28.78%	594 $3,000
Q4 2021 Feb 10, 2022	SELL	$5.7 - $9.1 $3,596 - $5,742	-631 Reduced 43.07%	834 $5,000
Q3 2021 Nov 10, 2021	BUY	$6.74 - $8.02 $9,874 - $11,749	1,465 New	1,465 $10,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.